Neurosterix — precision neuropsychiatric drug discovery

Neurosterix Raises $105M Series B to Build the Next Generation of Neuropsychiatric Therapies

November 18, 2026

When a startup raises money in the neuropsychiatry space, the news carries extra weight. This is a field where many drug developers have tried and stumbled, where patients live with conditions that existing medicines can barely touch. When Neurosterix announced a $105 million Series B on November 11, 2026, it was not just a capital event — it was a signal that a new approach to brain medicine may be finally coming of age.

Related

A Company Built on Precision

Neurosterix was founded with a specific scientific thesis: that allosteric modulators — molecules that change the shape and behaviour of a target protein rather than simply blocking or activating it — can unlock a level of precision in brain medicine that conventional drugs cannot reach. The company describes its mission as harnessing the power of allosteric modulators to design targeted, next-generation therapies for complex neuropsychiatric disorders.

The company operates across two locations: Geneva, Switzerland and Boston, Massachusetts. That geography is intentional. Geneva sits at the heart of European biomedical research and regulatory expertise. Boston anchors the company in one of the world's deepest pools of neuroscience talent, venture capital, and clinical infrastructure. The dual-hub model lets Neurosterix draw on both continents without compromising on scientific depth.

What the Series B Represents

The $105 million Series B announced on November 11, 2026 is a significant vote of confidence from investors who understand how hard neuropsychiatry drug development is. The field has historically high failure rates. Many large pharmaceutical companies scaled back their neuroscience programmes over the past decade after a string of expensive clinical trial failures. That retreat created space for smaller, more nimble biotech firms to enter with differentiated science — but the bar for investor confidence remains high.

Closing this round tells the market that Neurosterix's allosteric modulator approach has earned serious institutional backing. The capital is expected to advance the company's pipeline of candidates targeting neuropsychiatric disorders — conditions that affect hundreds of millions of people globally and remain significantly undertreated.

The company has not yet disclosed the full details of which programmes this round will accelerate, but its stated focus on precision by design — using the structural specificity of allosteric modulation — positions it at the more mechanistically sophisticated end of neuropsychiatry drug discovery.

Why Allosteric Modulation Matters

Most drugs that act on the nervous system work by sitting in the main active site of a receptor or enzyme and either switching it on or off. Allosteric modulators work differently. They bind to a separate site on the protein and change its three-dimensional shape, fine-tuning how it responds to natural signals in the body rather than replacing those signals outright. The result, in theory, is a more natural-feeling intervention with a reduced risk of side effects that come from forcing a receptor fully on or fully off.

For conditions like treatment-resistant depression, schizophrenia, anxiety disorders, and others in the neuropsychiatric space, that level of modulation could matter enormously. These conditions involve complex neural circuits where blunt-force pharmacology has often produced as many problems as it solved. Neurosterix's bet is that allosteric precision can change that outcome.

The Science Behind the Company

Neurosterix describes its scientific foundation as one built for complexity. Neuropsychiatric disorders rarely stem from a single dysfunctional protein. They arise from disrupted networks, altered receptor dynamics, and systemic changes in how brain circuits communicate. Allosteric modulators, by working with the body's own signalling rhythms, offer a tool that can intervene in those networks with more surgical accuracy.

The company's pipeline specifics are not fully public, but its dual-geography base — Geneva's regulatory and research environment combined with Boston's clinical trial infrastructure — suggests a development path designed from the ground up with regulatory readiness in mind. This is not a company that is thinking about an IND filing as a distant future event; it is building towards it in the way its operations are structured.

What This Means for Singapore, China, and Asian Startups

Neurosterix is based in Geneva and Boston, not in Asia. That distinction matters, and nothing in this article should be read to suggest otherwise. But the Neurosterix story is directly relevant to the biotech and health-tech ecosystems developing across Singapore, China, and the broader Asia-Pacific region.

Neuropsychiatric disorders carry a particularly heavy burden in Asia. Depression, anxiety, and related conditions affect hundreds of millions of people across the region, and the treatment gap — the difference between the number of people who need care and those who receive it — remains vast. Local startups, research institutions, and pharmaceutical companies working in this space should be watching closely what differentiated scientific approaches like allosteric modulation can achieve.

Singapore, in particular, has been building its biomedical sciences ecosystem with intention for more than two decades. A.STAR, the National University of Singapore, Duke-NUS Medical School, and a growing number of private biotech firms are all working in adjacent spaces. The Neurosterix raise is a reminder that precision science, not just large-scale screening programmes, can attract institutional capital — and that the same opportunity exists for founders and researchers in Asia who are willing to go deep on mechanism rather than broad on molecule count.

China's biotech sector has matured rapidly and produced globally competitive companies in oncology and immunology. Neuropsychiatry, however, remains relatively underserved, in part because of the complexity of the science and in part because of historical stigma around brain health conditions. The Neurosterix model — precise mechanism, strong academic grounding, dual geography — could serve as a template for Chinese founders building in this space with global ambitions.

For founders across Asia who are pre-Series A: the Neurosterix raise at $105 million suggests the market is ready to back well-founded mechanistic stories in neuro. If your science is differentiated and your team can explain why the mechanism is better — not just different — that is the case worth building.

how can ASIA startups compete globally

One underappreciated factor that separates funded startups from unfunded ones — especially before Series A — is the ability to communicate complex science clearly to people who did not spend a decade in a lab. According to the Sjodin Communications State of Sales Presentations (Phase Three, 2025), a primary survey of 1,075 respondents, 55% of study participants reported receiving little or no presentation skills training. That gap matters most precisely when the stakes are highest: when you are standing in front of investors, clinical partners, or regulatory bodies and you need them to follow you into an idea that is genuinely difficult. Speaking skills and presentation skills are not soft skills. They are the mechanism by which your science reaches the people who can fund it, approve it, or prescribe it.


Interested in improving your team's presentation and speaking skills?
Our founder Jason Lim works with startup teams on exactly this. Book a free class at https://start.dreamaker.club/jason

Related

Jason Lim

Jason Lim

I wanted more than just survival—I wanted control, options, and a life on my terms. The obsession with this goal led me to several places and acquired unique skillsets, in order to accomplish my goals. I found the secrets in my rock bottom, now I want to share them with you

Instagram logo icon
Youtube logo icon
Back to Blog